Jacobson Pharma Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Jacobson Pharma heeft een totaal eigen vermogen van HK$2.5B en een totale schuld van HK$652.4M, wat de schuld-eigenvermogensverhouding op 26.6% brengt. De totale activa en totale passiva bedragen respectievelijk HK$3.6B en HK$1.2B. De EBIT Jacobson Pharma is HK$341.2M waardoor de rentedekking 14.2 is. Het heeft contanten en kortetermijnbeleggingen van HK$515.9M.
Belangrijke informatie
26.6%
Verhouding schuld/eigen vermogen
HK$652.40m
Schuld
| Rente dekkingsratio | 14.2x |
| Contant | HK$515.90m |
| Aandelen | HK$2.46b |
| Totaal verplichtingen | HK$1.15b |
| Totaal activa | HK$3.61b |
Recente financiële gezondheidsupdates
These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well
Jun 20
Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?
Feb 09Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden
Jan 11Recent updates
There's Reason For Concern Over Jacobson Pharma Corporation Limited's (HKG:2633) Massive 27% Price Jump
Nov 22Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now
Aug 21Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues
Dec 21Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025
Nov 27These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well
Jun 20Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Nov 28Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268
Sep 25Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?
Sep 16Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 28Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Jul 14Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?
Feb 09Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012
Nov 29Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015
Sep 24Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year
Sep 16Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares
Feb 03
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)
Jan 24Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden
Jan 11Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?
Dec 27Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?
Dec 12Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years
Dec 03Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( HK$1.1B ) 2633 } overtreffen de korte termijn passiva ( HK$516.5M ).
Langlopende schulden: De kortetermijnactiva 2633 ( HK$1.1B ) overtreffen de langetermijnschulden ( HK$634.5M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 5.6% ) 2633 wordt als voldoende beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van 2633 is de afgelopen 5 jaar gedaald van 54% naar 26.6%.
Schuldendekking: De schuld van 2633 wordt goed gedekt door de operationele kasstroom ( 74.2% ).
Rentedekking: De rentebetalingen op de schuld van 2633 worden goed gedekt door EBIT ( 14.2 x dekking).